



## AUX INTERNATIONAL HOLDINGS LIMITED

### 奧克斯國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2080)

#### FORM OF PROXY FOR USE AT EXTRAORDINARY GENERAL MEETING

I/We (Name) \_\_\_\_\_ (Block capitals, please) of  
(Address) \_\_\_\_\_ being the holder(s) of  
\_\_\_\_\_ (see Note 1) shares of HK\$0.01 each in the capital of  
AUX International Holdings Limited (the “Company”) hereby appoint (Name) \_\_\_\_\_  
of (Address) \_\_\_\_\_ or failing his/her (Name)  
\_\_\_\_\_ of (Address) \_\_\_\_\_

or failing him/her, the chairman of the meeting (see Note 2) as my/our proxy to attend and vote for me/us and on my/our behalf at the extraordinary general meeting (“Meeting”) of the Company to be held at Portion 2, 12/F, The Center, 99 Queen’s Road Central, Central, Hong Kong on Tuesday, 20 February 2024 at 12:00 noon and at any adjournment thereof or on any resolution or motion which is proposed thereat. My/our proxy is authorised and instructed to vote as indicated (see Note 3) in respect of the undermentioned resolutions:

Ordinary Resolutions (see Note 3)		For	Against
1.	<p><b>“THAT</b></p> <p>(a) 2023 Framework Agreement I (as defined in the circular of the Company dated 2 February 2024 (the “Circular”) and a copy of which is tabled at the Meeting and marked “A” and initialled by the chairman of the Meeting for identification purpose) and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;</p> <p>(b) the annual caps in respect of the transactions contemplated under 2023 Framework Agreement I in the amounts of RMB30.6 million, RMB33.7 million and RMB41.5 million for the three years ending 31 December 2024, 31 December 2025 and 31 December 2026 respectively be and are hereby approved; and</p> <p>(c) any director of the Company (the “Director”) or any other person authorised by the board of Directors be and is hereby authorised to do and execute all such acts, matters, deeds, documents and things as he/she may in his/her absolute discretion consider necessary, desirable or expedient for or in connection with the implementation of 2023 Framework Agreement I and all transactions and other matters contemplated thereunder or ancillary thereto, to agree to any waiver of compliance with or amendment or supplement to any of the provisions of 2023 Framework Agreement I which is in his/her opinion not of a material nature and necessary, desirable or expedient for or in connection with the implementation of 2023 Framework Agreement I and all transactions and other matters contemplated thereunder or ancillary thereto, and to effect or implement any other matter referred to in this resolution.”</p>		
2.	<p><b>“THAT</b></p> <p>(a) 2023 Framework Agreement II (as defined in the Circular and a copy of which is tabled at the Meeting and marked “B” and initialled by the chairman of the Meeting for identification purpose) and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;</p> <p>(b) the annual caps in respect of the transactions contemplated under 2023 Framework Agreement II in the amounts of RMB1.2 million, RMB1.2 million and RMB1.2 million for the three years ending 31 December 2024, 31 December 2025 and 31 December 2026 respectively be and are hereby approved; and</p> <p>(c) any Director or any other person authorised by the board of Directors be and is hereby authorised to do and execute all such acts, matters, deeds, documents and things as he/she may in his/her absolute discretion consider necessary, desirable or expedient for or in connection with the implementation of 2023 Framework Agreement II and all transactions and other matters contemplated thereunder or ancillary thereto, to agree to any waiver of compliance with or amendment or supplement to any of the provisions of 2023 Framework Agreement II which is in his/her opinion not of a material nature and necessary, desirable or expedient for or in connection with the implementation of 2023 Framework Agreement II and all transactions and other matters contemplated thereunder or ancillary thereto, and to effect or implement any other matter referred to in this resolution.”</p>		

<b>Ordinary Resolutions (see Note 3)</b>		<b>For</b>	<b>Against</b>
3.	<p><b>“THAT</b></p> <p>(a) Amended 2023 Framework Agreement III (as defined in the Circular and a copy of which is tabled at the Meeting and marked “C” and initialled by the chairman of the Meeting for identification purpose) and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;</p> <p>(b) the annual caps in respect of the transactions contemplated under Amended 2023 Framework Agreement III in the amounts of RMB13.5 million, RMB14.5 million and RMB15.1 million for the three years ending 31 December 2024, 31 December 2025 and 31 December 2026 respectively be and are hereby approved; and</p> <p>(c) any Director or any other person authorised by the board of Directors be and is hereby authorised to do and execute all such acts, matters, deeds, documents and things as he/she may in his/her absolute discretion consider necessary, desirable or expedient for or in connection with the implementation of Amended 2023 Framework Agreement III and all transactions and other matters contemplated thereunder or ancillary thereto, to agree to any waiver of compliance with or amendment or supplement to any of the provisions of Amended 2023 Framework Agreement III which is in his/her opinion not of a material nature and necessary, desirable or expedient for or in connection with the implementation of Amended 2023 Framework Agreement III and all transactions and other matters contemplated thereunder or ancillary thereto, and to effect or implement any other matter referred to in this resolution.”</p>		
4.	<p><b>“THAT</b></p> <p>(a) 2023 Framework Agreement IV (as defined in the Circular and a copy of which is tabled at the Meeting and marked “D” and initialled by the chairman of the Meeting for identification purpose) and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;</p> <p>(b) the annual caps in respect of the transactions contemplated under 2023 Framework Agreement IV in the amounts of RMB37.5 million, RMB31.5 million and RMB28.0 million for the three years ending 31 December 2024, 31 December 2025 and 31 December 2026 respectively be and are hereby approved; and</p> <p>(c) any Director or any other person authorised by the board of Directors be and is hereby authorised to do and execute all such acts, matters, deeds, documents and things as he/she may in his/her absolute discretion consider necessary, desirable or expedient for or in connection with the implementation of 2023 Framework Agreement IV and all transactions and other matters contemplated thereunder or ancillary thereto, to agree to any waiver of compliance with or amendment or supplement to any of the provisions of 2023 Framework Agreement IV which is in his/her opinion not of a material nature and necessary, desirable or expedient for or in connection with the implementation of 2023 Framework Agreement IV and all transactions and other matters contemplated thereunder or ancillary thereto, and to effect or implement any other matter referred to in this resolution.”</p>		
5.	<p><b>“THAT</b></p> <p>(a) 2023 Framework Agreement V (as defined in the Circular and a copy of which is tabled at the Meeting and marked “E” and initialled by the chairman of the Meeting for identification purpose) and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;</p> <p>(b) the annual caps in respect of the transactions contemplated under 2023 Framework Agreement V in the amounts of RMB8.6 million, RMB9.9 million and RMB10.7 million for the three years ending 31 December 2024, 31 December 2025 and 31 December 2026 respectively be and are hereby approved; and</p> <p>(c) any Director or any other person authorised by the board of Directors be and is hereby authorised to do and execute all such acts, matters, deeds, documents and things as he/she may in his/her absolute discretion consider necessary, desirable or expedient for or in connection with the implementation of 2023 Framework Agreement V and all transactions and other matters contemplated thereunder or ancillary thereto, to agree to any waiver of compliance with or amendment or supplement to any of the provisions of 2023 Framework Agreement V which is in his/her opinion not of a material nature and necessary, desirable or expedient for or in connection with the implementation of 2023 Framework Agreement V and all transactions and other matters contemplated thereunder or ancillary thereto, and to effect or implement any other matter referred to in this resolution.”</p>		

Ordinary Resolutions (see Note 3)		For	Against
6.	<p><b>“THAT</b></p> <p>with effect from the date of passing of this resolution, the provisions of the 2023 Share Option (as defined in the Circular and a copy of which is tabled at the meeting and marked “F” and initialled by the chairman of the meeting for identification purpose), be and are hereby approved and adopted as the share option scheme of the Company and that the Directors be and are hereby authorised to approve any amendment to the provisions of the 2023 Share Option Scheme as may be acceptable or not objected to by The Stock Exchange of Hong Kong Limited, to grant options to subscribe for shares of the Company thereunder at the Directors’ sole and absolute discretion, to allot, issue and deal with shares of the Company pursuant to the exercise of options granted thereunder from time to time, and to do all such acts and enter into all such transactions and arrangements as may be necessary or expedient in order to give effect thereto.”</p>		

Dated this \_\_\_\_\_ day of \_\_\_\_\_ 2024

Signature(s) (Note 5) \_\_\_\_\_

*Notes:*

1. Please insert the number of shares registered in your name(s); if no number is inserted, this form of proxy will be deemed to relate to all the shares in the capital of the Company registered in your name(s).
2. A member may appoint more than one proxy of his/her own choice. If such an appointment is made, please strike out the words “or failing him/her, the chairman of the meeting”, and insert the name(s) of the person(s) appointed as proxy in space provided. Any alteration made to this form of proxy must be initialled by the person who signs it.
3. **IMPORTANT: IF YOU WISH TO VOTE FOR ANY RESOLUTION, PLEASE TICK THE BOX MARKED “For”. IF YOU WISH TO VOTE AGAINST ANY RESOLUTION, PLEASE TICK THE BOX MARKED “Against”.** Failure to tick a box will entitle your proxy to cast your vote in relation to the relevant resolution at his/her discretion. Your proxy will also be entitled to vote at his/her discretion on any resolution properly put to the Meeting other than those referred to in the notice convening the Meeting.
4. If the appointor is a corporation, this form must be under common seal or under the hand of an officer, attorney, or other person duly authorized on that behalf.
5. In the case of joint holders, the signature of any one holder will be sufficient but the names of all the joint holders should be stated. Where there are joint holders of any share of the Company, any one of such joint holders may vote at the Meeting, either in person or by proxy, in respect of such share as if he/she were solely entitled thereto, but if more than one of such joint holders be present at the Meeting, whether in person or by proxy, that one of the said persons so present whose name stands first on the register of members in respect of such share shall alone be entitled to vote in respect thereof.
6. In order to be valid, this form of proxy together with the power of attorney or other authority (if any) under which it is signed, or a notarially certified copy of such power of attorney authority, must be deposited at the Company’s branch share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not less than 48 hours before the time for holding the Meeting (i.e. at or before 12:00 noon on Sunday, 18 February 2024) or any adjournment thereof. The completion and return of the form of proxy shall not preclude shareholders of the Company from attending and voting in person at the above Meeting (or any adjourned meeting thereof) if they so wish.
7. A proxy need not be a shareholder of the Company.